Beiersdorf, the renowned company behind iconic brands such as Nivea and Eucerin, has announced a new partnership with Macro Biologics, Inc., aimed at developing biodegradable antimicrobial peptides for applications in both skin care and healthcare. This long-term collaboration will explore the potential of Macro Biologics' innovative antimicrobial peptides, known as "Amicidins", in the creation of dermatological products and healthcare solutions.
In addition to strengthening its leadership in sector innovation, Beiersdorf has also become a strategic investor in Macro Biologics through its Oscar & Paul Corporate Venture Capital unit. This move underscores Beiersdorf's commitment to delivering transformative and sustainable solutions to its consumers, in line with its "Win with Care" strategy and its ambition to remain at the forefront of climate care.
Amicidins, antimicrobial peptides developed by Macro Biologics, are notable for their ability to combat a wide range of bacteria, making them a potential ally in treating skin conditions and preventing wound infections through local applications. This development aligns with the shared goal of both companies: to offer highly effective, safe, and sustainable solutions in various application areas across Beiersdorf's brand portfolio, with a focus on dermatological and healthcare care.
Dr Gitta Neufang, Senior Vice President of Global R&D at Beiersdorf, highlighted the importance of the collaboration: "Through our partnership with Macro Biologics, we enhance Beiersdorf’s innovation capabilities in line with our 'Win with Care' strategy, as well as our commitment to climate leadership. We are excited to have found an outstanding partner in this promising field of antimicrobial peptides, who shares our vision of transformative innovation."
Dr Michael Bevilacqua, CEO and CSO of Macro Biologics, commented: "We are thrilled to partner with Beiersdorf, a global leader in skin care and healthcare. This collaboration is a perfect fit from both a research and business perspective. Beiersdorf’s extensive expertise in product formulation and commercialisation will amplify the impact of Amicidins to improve people’s lives in a sustainable way."
This partnership marks a key step towards the future of dermatological and healthcare innovation, paving the way for products that not only care for the skin but also promote environmental wellbeing.